Comparison
Tirzepatide Versus Retatrutide
Retatrutide is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors. It is not FDA approved and is not legitimately available outside a clinical trial. Comparing it with tirzepatide means comparing an approved medicine against an unapproved candidate whose phase 3 results and safety profile are not established.
Key takeaways
- Retatrutide is investigational and not approved for any indication.
- It targets three receptors — GIP, GLP-1, and glucagon — versus tirzepatide's two.
- No head-to-head randomised comparison with tirzepatide is cited here.
- Early-phase effect sizes commonly attenuate in larger phase 3 trials.
- Any product sold as retatrutide outside a clinical trial is not legitimate.
| Retatrutide status | Investigational — not FDA approved |
|---|---|
| Receptors targeted | GIP, GLP-1, and glucagon |
| Tirzepatide status | FDA approved (Zepbound, Mounjaro) |
| Head-to-head evidence | None cited |
| Legitimate access | Registered clinical trial only |
Why can't early retatrutide results be compared with tirzepatide's?
Because they come from different trial phases with different populations, durations, and endpoints. Phase 2 trials are smaller, shorter, and more selectively enrolled, and effect sizes reliably shrink as trials scale. A phase 2 headline placed next to a phase 3 result is not a comparison; it is a category error that consistently favours the earlier-stage drug.
What is the risk in the grey market?
Substantial. Because retatrutide is unapproved, anything sold under that name outside a trial comes from an unregulated supply chain with no verification of identity, purity, concentration, or sterility. There is no pharmacy accountability, no adverse-event reporting pathway, and no recourse.
This site does not link to, name, or describe how to obtain such products.
What the evidence shows
- Retatrutide's investigational status and receptor targets.
- Tirzepatide's approved status and randomised evidence base.
What the evidence does not show
- That retatrutide is more effective — no head-to-head evidence is cited.
- That early-phase results predict phase 3 outcomes.
- Any legitimate consumer access pathway for an unapproved drug.
Related: Pipeline research
How large is the effect across the verified trials?
| Trial arm | Point estimate | Range | N |
|---|---|---|---|
| SURMOUNT-1 · 15 mg | 20.9% | 19.5% to 22.3% | 2,539 |
| SURMOUNT-1 · 10 mg | 19.5% | 18.2% to 20.8% | 2,539 |
| SURMOUNT-1 · 5 mg | 15.0% | 13.8% to 16.2% | 2,539 |
| SURMOUNT-2 · 15 mg | 14.7% | 13.4% to 16.0% | 938 |
| SURMOUNT-2 · 10 mg | 12.8% | 11.5% to 14.1% | 938 |
| SURMOUNT-1 · placebo | 3.1% | 2.3% to 3.9% | 2,539 |
| Series | Wk 0 | Wk 12 | Wk 24 | Wk 40 | Wk 56 | Wk 72 |
|---|---|---|---|---|---|---|
| Tirzepatide 15 mg | 0% | -6.5% | -12.4% | -16.8% | -19.3% | -20.9% |
| Tirzepatide 5 mg | 0% | -5.1% | -9.3% | -12.4% | -14.2% | -15.0% |
| Placebo | 0% | -1.4% | -2.3% | -2.8% | -3.0% | -3.1% |
When was each piece of this evidence established?
| Date | Event |
|---|---|
| May 2022 | Tirzepatide approved as Mounjaro for type 2 diabetes |
| Jun 2022 | SURMOUNT-1 published in the New England Journal of Medicine |
| Jul 2023 | SURMOUNT-2 published in the Lancet |
| Nov 2023 | Tirzepatide approved as Zepbound for chronic weight management |
| Dec 2023 | SURMOUNT-4 withdrawal results published in JAMA |
| Jun 2024 | SURMOUNT-OSA published; obstructive sleep apnoea evidence established |
| May 2025 | SURMOUNT-5 head-to-head against semaglutide published in NEJM |
What does this page cover, and what does it deliberately leave out?
This page addresses Approved versus investigational status and mechanisms and evidence, organised around the primary question of tirzepatide vs retatrutide. Each of those elements is treated separately below rather than blended, because they carry different evidence weights and a reader is entitled to know which parts rest on randomised data and which rest on a captured commercial claim or a regulatory document.
| Element | Treatment here | Evidence basis |
|---|---|---|
| Approved versus investigational status | Covered on this page | Primary evidence |
| Mechanisms and evidence | Covered on this page | Primary evidence |
| Individualized clinical instruction | Deliberately not covered | Belongs with a prescriber who knows your history |
What are the limits of what this page can tell you?
Every page on this site rests on a specific clinical evidence, and that record has boundaries worth stating plainly rather than leaving a reader to discover them. The limitations below are specific to the material presented above.
- The evidence here describes groups, populations, or captured records — it does not describe you, and no page can substitute for a prescriber who knows your history.
- Figures carry the date on which they were verified. In a market where terms change frequently, an undated figure functions as a claim about the present that nobody has checked.
- Elements marked Verification Pending are genuinely unknown to this publication rather than merely omitted for brevity, and should not be inferred from surrounding content.
- Where a source conflicts with another, this site shows the conflict rather than resolving it, which means some questions are left open on purpose.
What would change the conclusion on this page?
This conclusion is held open to the following evidence:
- New primary evidence bearing directly on tirzepatide vs retatrutide.
- A change to FDA labelling affecting any statement made above.
- A verified correction submitted through the corrections process and accepted on the evidence.
- A material change to a captured record, including a price, term, or regulatory status.
- Completion of a verification currently marked pending, which would replace a gap with a stated fact.
What do the technical terms on this page mean?
Definitions for the 4 technical terms this page uses, including GIP, GLP-1, endpoint, placebo — in the specific sense used above.
| GIP | Glucose-dependent insulinotropic polypeptide. An incretin hormone released by the small intestine after eating. Tirzepatide activates its receptor alongside the GLP-1 receptor, which is the feature that distinguishes it from single-agonist drugs such as semaglutide. |
|---|---|
| GLP-1 | Glucagon-like peptide-1. An incretin hormone that slows gastric emptying, signals satiety to the brain, stimulates glucose-dependent insulin release, and suppresses inappropriate glucagon secretion. |
| endpoint | The outcome a trial is designed to measure. A primary endpoint is specified before the trial begins; secondary and exploratory endpoints carry progressively weaker inferential weight. |
| placebo | An inactive comparator given so that the effect of the drug can be separated from the effect of being in a trial. Placebo groups in the SURMOUNT trials still lost some weight, which is why the placebo-subtracted difference matters more than the raw figure. |
Frequently asked questions
Is retatrutide better than tirzepatide?
No head-to-head trial is cited here, and retatrutide is investigational rather than approved.
Can I get retatrutide?
Only through a registered clinical trial. Products sold outside that are not legitimate.
What is a triple agonist?
An agent targeting GIP, GLP-1, and glucagon receptors, versus tirzepatide's two receptors.
Why do early trial results look so strong?
Phase 2 trials are smaller and more selective; effect sizes commonly attenuate at scale.
Change history
| Date | Change |
|---|---|
| 2026-07-22 | Page published with current dataset snapshot. |
Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.